CRISPR Therapeutics AG (CRSP) closed at $43.42 in the latest trading session, marking a -1.83% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.29%.

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options become available today, for the March 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

Loughborough’s Centre for Research in Social Policy (CRSP) has secured a further four-year partnership with the Joseph Rowntree Foundation (JRF) to continue its work defining socially acceptable ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

20:42 EST Cathie Wood’s ARK Investment bought 133K shares of Crispr Therapeutics (CRSP) today Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), with a price target of $85.00.

The most recent trading session ended with CRISPR Therapeutics AG (CRSP) standing at $38.36, reflecting a -1.26% shift from the previouse trading day's closing. The stock trailed the S&P 500 ...

Buy CRSP near 32.79 target 40.06 stop loss @ 32.7 Details The technical summary data tells us to buy CRSP near 32.79 with an upside target of 40.06. This data also tells us to set a stop loss @ 32.7 ...